GSK2194069 是脂肪酸合成酶 (FASN) 的 β-酮基还原酶 (KR) 的有效抑制剂,IC50为 7.7 nM。GSK2194069 通过作用乙酰乙酰辅酶 A、NADPH (IC50或 Ki分别为 4.8 nM 和 5.6 nM) ,抑制表达FAS的癌细胞。
生物活性 | GSK2194069 is a potent inhibitor of β-ketoyl reductase (KR) offatty acid synthase(FASN), with anIC50value of 7.7 nM. GSK2194069 shows specifically inhibitory effect onFASexpressingcancercells, by acting potent efficacy on acetoacetyl-CoA, NADPH with IC50or Kivalues of 4.8 nM and 5.6 nM, respectively[1][2][3]. |
体外研究 (In Vitro) | GSK2194069 (100 nM; 24 h) inhibits fatty acid synthase (FAS) in cancer cell lines (KATO-III, MKN45, A549, SNU-1) without reducing FAS production protein level[1]. GSK2194069 decreases phosphatidylcholine levels in A549 cells with a half-maximum effective concentration (EC50) value of 15.5 ± 9 nM (n = 78), correlating with the decreased palmitate synthesis[1]. GSK2194069 (5 μM and 20 μM) shows higher efficacy in FASN-positive LNCaP cells rather than FASN-negative PC3 cells, with the higher FASN Expression level in LNCaP cells[2]. GSK2194069 (50 μM; 24 h) inhibits the growth of LNCaP-LN3 human prostate cancer cells[3]. GSK2194069 (60.4 nM; 24 h) displays properties of metabolomics, including L-acetyl carnitine, stearoyl carnitine, vaccenyl carnitine, and palmitoyl-L-carnitine decrease in LNCaP-LN3 cells[3].
Western Blot Analysis[1] Cell Line: | A549 | Concentration: | 0, 10, 100, 1000 nM | Incubation Time: | 48 hours or 120 hours | Result: | Didn’t decrease FAS protein level. |
Western Blot Analysis[2] Cell Line: | FASN-positive LNCaP cells, and FASN-negative PC3 cells | Concentration: | 1 nM-0.1 mM | Incubation Time: | 48 hours | Result: | Inhibited tumor cells growth significantly, and reduced LNCaP cells much better. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : ≥ 100 mg/mL(233.38 mM) *"≥" means soluble, but saturation unknown. 配制储备液 1 mM | 2.3338 mL | 11.6692 mL | 23.3383 mL | 5 mM | 0.4668 mL | 2.3338 mL | 4.6677 mL | 10 mM | 0.2334 mL | 1.1669 mL | 2.3338 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (5.83 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (5.83 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (5.83 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (5.83 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (5.83 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (5.83 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|